scholarly journals P456 Drug survival of thiopurine–allopurinol combination therapy in a real-life population-based cohort

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S335-S335
Author(s):  
J E Kreijne ◽  
R C de Veer ◽  
N K de Boer ◽  
G Bouma ◽  
G Dijkstra ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Real Life ◽  
Population Based ◽  
Drug Survival

scholarly journals Multi-GPU approach to global induction of classification trees for large-scale data mining

2021 ◽  
Author(s):  
Krzysztof Jurczuk ◽  
Marcin Czajkowski ◽  
Marek Kretowski
Keyword(s):  
Data Mining ◽  
Large Scale ◽  
Real Life ◽  
Population Based ◽  
Tree Structure ◽  
Global Approach ◽  
Data Parallel ◽  
Large Scale Data ◽  
The Impact ◽  
Scale Data

AbstractThis paper concerns the evolutionary induction of decision trees (DT) for large-scale data. Such a global approach is one of the alternatives to the top-down inducers. It searches for the tree structure and tests simultaneously and thus gives improvements in the prediction and size of resulting classifiers in many situations. However, it is the population-based and iterative approach that can be too computationally demanding to apply for big data mining directly. The paper demonstrates that this barrier can be overcome by smart distributed/parallel processing. Moreover, we ask the question whether the global approach can truly compete with the greedy systems for large-scale data. For this purpose, we propose a novel multi-GPU approach. It incorporates the knowledge of global DT induction and evolutionary algorithm parallelization together with efficient utilization of memory and computing GPU’s resources. The searches for the tree structure and tests are performed simultaneously on a CPU, while the fitness calculations are delegated to GPUs. Data-parallel decomposition strategy and CUDA framework are applied. Experimental validation is performed on both artificial and real-life datasets. In both cases, the obtained acceleration is very satisfactory. The solution is able to process even billions of instances in a few hours on a single workstation equipped with 4 GPUs. The impact of data characteristics (size and dimension) on convergence and speedup of the evolutionary search is also shown. When the number of GPUs grows, nearly linear scalability is observed what suggests that data size boundaries for evolutionary DT mining are fading.

scholarly journals Blood Coagulation Algorithm: A Novel Bio-Inspired Meta-Heuristic Algorithm for Global Optimization

Mathematics ◽  
2021 ◽  
Vol 9 (23) ◽  
pp. 3011
Author(s):  
Drishti Yadav
Keyword(s):  
Blood Coagulation ◽  
Heuristic Algorithms ◽  
Cooperative Behavior ◽  
Real Life ◽  
Search Space ◽  
Population Based ◽  
Test Analysis ◽  
Search Spaces ◽  
Consistent Performance ◽  
The Comparative Study

This paper introduces a novel population-based bio-inspired meta-heuristic optimization algorithm, called Blood Coagulation Algorithm (BCA). BCA derives inspiration from the process of blood coagulation in the human body. The underlying concepts and ideas behind the proposed algorithm are the cooperative behavior of thrombocytes and their intelligent strategy of clot formation. These behaviors are modeled and utilized to underscore intensification and diversification in a given search space. A comparison with various state-of-the-art meta-heuristic algorithms over a test suite of 23 renowned benchmark functions reflects the efficiency of BCA. An extensive investigation is conducted to analyze the performance, convergence behavior and computational complexity of BCA. The comparative study and statistical test analysis demonstrate that BCA offers very competitive and statistically significant results compared to other eminent meta-heuristic algorithms. Experimental results also show the consistent performance of BCA in high dimensional search spaces. Furthermore, we demonstrate the applicability of BCA on real-world applications by solving several real-life engineering problems.

scholarly journals Blood Neutrophil Counts are Associated with Exacerbation Frequency and Mortality in COPD

2020 ◽  
Author(s):  
Mike Lonergan ◽  
Alison J Dicker ◽  
Megan L Crichton ◽  
Holly R Keir ◽  
Melissa K. Van Dyke ◽  
...  
Keyword(s):  
Large Population ◽  
Real Life ◽  
Population Based ◽  
Blood Eosinophil ◽  
Blood Neutrophil ◽  
Disease Heterogeneity ◽  
Disease Information ◽  
Increased Risk ◽  
Eosinophil Counts

Abstract Background Identifying patients with COPD at increased risk of poor outcomes is challenging due to disease heterogeneity. Potential biomarkers need to be readily available in real-life clinical practice. Blood eosinophil counts are widely studied but few studies have examined the prognostic value of blood neutrophil counts (BNC). Methods In a large population-based COPD registry in the East of Scotland (TARDIS: Tayside Allergic and Respiratory Disease Information System), BNC were compared to measures of disease severity and mortality over up to 15 years follow-up. Potential mechanisms of disease modification by BNC were explored in a nested microbiome substudy. Results 178120 neutrophil counts were obtained from 7220 people (mean follow up 9 years) during stable disease periods. Median BNC was 5200cells/µL (IQR 4000-7000cells/µL). Mortality rates among those 34% with elevated BNCs (defined as 6000-15000cells/µL) at the study start were 80% higher (14.0/100 person years v 7.8/100py, P<0.001) than those with BNC in the normal range (2000-6000cells/µL). People with elevated BNC were more likely to be classified as GOLD D (46% v 33% P<0.001), have more exacerbations (mean 2.3 v 1.3/year, P<0.001), and were more likely to have severe exacerbations (13% vs. 5%, P<0.001) in the following year. Eosinophil counts were much less predictive of these outcomes. In a sub-cohort (N=276), patients with elevated BNC had increased relative abundance of Proteobacteria and reduced microbiome diversity. Conclusion High BNC may provide a useful indicator of risk of exacerbations and mortality in COPD patients.

scholarly journals Optimizing community detection in social networks using antlion and K-median

2019 ◽  
Vol 8 (4) ◽  
Author(s):  
Amany A. Naem ◽  
Neveen I. Ghali
Keyword(s):  
Social Networks ◽  
Objective Function ◽  
Community Detection ◽  
Optimization Problem ◽  
Real Life ◽  
Optimization Methods ◽  
Population Based ◽  
Detection Problem ◽  
Network Communities ◽  
Antlion Optimization

Antlion Optimization (ALO) is one of the latest population based optimization methods that proved its good performance in a variety of applications. The ALO algorithm copies the hunting mechanism of antlions to ants in nature. Community detection in social networks is conclusive to understanding the concepts of the networks. Identifying network communities can be viewed as a problem of clustering a set of nodes into communities. k-median clustering is one of the popular techniques that has been applied in clustering. The problem of clustering network can be formalized as an optimization problem where a qualitatively objective function that captures the intuition of a cluster as a set of nodes with better in ternal connectivity than external connectivity is selected to be optimized. In this paper, a mixture antlion optimization and k-median for solving the community detection problem is proposed and named as K-median Modularity ALO. Experimental results which are applied on real life networks show the ability of the mixture antlion optimization and k-median to detect successfully an optimized community structure based on putting the modularity as an objective function.

scholarly journals Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

2022 ◽  
Vol 15 (1) ◽  
pp. 95
Author(s):  
Giovanni Damiani ◽  
Giulia Odorici ◽  
Alessia Pacifico ◽  
Aldo Morrone ◽  
Rosalynn R. Z. Conic ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Rescue Therapy ◽  
Therapeutic Option ◽  
Real Life ◽  
Chronic Inflammatory Disease ◽  
Life Study ◽  
Secondary Failure ◽  
The Moment ◽  
Effective Drugs

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

scholarly journals Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study

2019 ◽  
Vol Volume 11 ◽  
pp. 207-216 ◽  
Author(s):  
Bente Arboe ◽  
Maja Halgren Olsen ◽  
Jette Sønderskov Gørløv ◽  
Anne Katrine Duun-Henriksen ◽  
Susanne Oksbjerg Dalton ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Real Life ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Treatment Intensity ◽  
Population Based Study ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Giovanni Cagnotto ◽  
Minna Willim ◽  
Jan-Åke Nilsson ◽  
Michele Compagno ◽  
Lennart T. H. Jacobsson ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Response ◽  
Cox Regression ◽  
Population Based ◽  
Drug Survival ◽  
Quality Register ◽  
High Pain Score ◽  
Selection Of Variables ◽  
National Quality ◽  
Significant Difference

Abstract Background There are limited data regarding efficacy of abatacept treatment for rheumatoid arthritis (RA) outside clinical trials. Quality registers have been useful for observational studies on tumor necrosis factor inhibition in clinical practice. The aim of this study was to investigate clinical efficacy and tolerability of abatacept in RA, using a national register. Methods RA patients that started abatacept between 2006 and 2017 and were included in the Swedish Rheumatology Quality register (N = 2716) were investigated. Survival on drug was estimated using Kaplan-Meier analysis. The European League Against Rheumatism (EULAR) good response and Health Assessment Questionnaire (HAQ) response (improvement of ≥ 0.3) rates (LUNDEX corrected for drug survival) at 6 and at 12 months were assessed. Predictors of discontinuation were investigated by Cox regression analyses, and predictors of clinical response by logistic regression. Significance-based backward stepwise selection of variables was used for the final multivariate models. Results There was a significant difference in drug survival by previous biologic disease-modifying antirheumatic drug (bDMARD) exposure (p < 0.001), with longer survival in bionaïve patients. Men (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.74–0.98) and methotrexate users (HR 0.85, 95% CI 0.76–0.95) were less likely to discontinue abatacept, whereas a high pain score predicted discontinuation (HR 1.14 per standard deviation, 95% CI 1.07–1.20). The absence of previous bDMARD exposure, male sex, and a low HAQ score were independently associated with LUNDEX-corrected EULAR good response. The absence of previous bDMARD exposure also predicted LUNDEX-corrected HAQ response. Conclusions In this population-based study of RA, bDMARD naïve patients and male patients were more likely to remain on abatacept with a major clinical response.

Sign in / Sign up

Export Citation Format

Share Document